Global Psychotropic Drug Market

Psychotropic Drug Comprehensive Study by End-users (Hospitals, Clinics, Others), Distribution Channel (Hospital pharmacies, Drug Stores, Retail Stores, E-Commerce), Drug Class (Anti-Depressants, Anti-Psychotics, Stimulants, Anxiolytics, Mood Stabilizers) Players and Region - Global Market Outlook to 2028

Psychotropic Drug Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Psychotropic Drug Market?

A psychotropic drug is any drug that affects behavior, mood, thoughts, or perception. It is used to treat a variety of mental health issues when those issues cause significant impairment to healthy functioning. These drugs are a broad category of drugs that treat many different conditions. There are five major classes of legal psychotropic medications, anti-anxiety agents, antidepressants, antipsychotics, mood stabilizers and stimulants.

Highlights from Psychotropic Drug Market Study
AttributesDetails
Study Period2018-2028
Base Year2022
UnitValue (USD Million)
Key Companies ProfiledIntas Pharmaceuticals Ltd. (India), Sun Pharmaceutical Industries Ltd. (India), Cadila Pharmaceuticals (India), Abbott Laboratories (United States), Sanofi S.A. (France), Cipla Limited (India), Biocon Limited (India), Lupin Limited (India), Emcure Pharmaceuticals Ltd. (India) and Novartis International AG (Switzerland)


The companies are exploring the market by adopting expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain competitive advantage through combined collaborations. Research Analyst at AMA predicts that Indian Players will contribute to the maximum growth of Global Psychotropic Drug market throughout the forecasted period.

Intas Pharmaceuticals Ltd. (India), Sun Pharmaceutical Industries Ltd. (India), Cadila Pharmaceuticals (India), Abbott Laboratories (United States), Sanofi S.A. (France), Cipla Limited (India), Biocon Limited (India), Lupin Limited (India), Emcure Pharmaceuticals Ltd. (India) and Novartis International AG (Switzerland) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Dr. Reddy’s Laboratories Limited (India) and Alkem Laboratories Limited (India).

Psychotropic Drug Market Segmentation:
ScopeSub-Segments
End-usersHospitals,Clinics,Others
Distribution ChannelHospital pharmacies,Drug Stores,Retail Stores,E-Commerce
Drug ClassAnti-Depressants,Anti-Psychotics,Stimulants,Anxiolytics,Mood Stabilizers


On the basis of geography, the market of Psychotropic Drug has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Increased Research and Development Activities

Market Growth Drivers:
Increased Prevalence of Psychotic Disorders and Increased Health Care Expenditure

Challenges:
Stringent Government Rules Regulations

Restraints:
High Cost of Advanced Treatments and Misuse of Psychoactive Drugs

Opportunities:
Growth in the Healthcare Industry Worldwide and Increasing Health Awareness Among People

Key Target Audience
Psychotropic Drug Manufacturers, Emerging Companies, Research Professionals and End-users




Report Objectives / Segmentation Covered

By End-users
  • Hospitals
  • Clinics
  • Others

By Distribution Channel
  • Hospital pharmacies
  • Drug Stores
  • Retail Stores
  • E-Commerce

By Drug Class
  • Anti-Depressants
  • Anti-Psychotics
  • Stimulants
  • Anxiolytics
  • Mood Stabilizers

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increased Prevalence of Psychotic Disorders
      • 3.2.2. Increased Health Care Expenditure
    • 3.3. Market Challenges
      • 3.3.1. Stringent Government Rules Regulations
    • 3.4. Market Trends
      • 3.4.1. Increased Research and Development Activities
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Psychotropic Drug, by End-users, Distribution Channel, Drug Class and Region (value, volume and price ) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Psychotropic Drug (Value)
      • 5.2.1. Global Psychotropic Drug by: End-users (Value)
        • 5.2.1.1. Hospitals
        • 5.2.1.2. Clinics
        • 5.2.1.3. Others
      • 5.2.2. Global Psychotropic Drug by: Distribution Channel (Value)
        • 5.2.2.1. Hospital pharmacies
        • 5.2.2.2. Drug Stores
        • 5.2.2.3. Retail Stores
        • 5.2.2.4. E-Commerce
      • 5.2.3. Global Psychotropic Drug by: Drug Class (Value)
        • 5.2.3.1. Anti-Depressants
        • 5.2.3.2. Anti-Psychotics
        • 5.2.3.3. Stimulants
        • 5.2.3.4. Anxiolytics
        • 5.2.3.5. Mood Stabilizers
      • 5.2.4. Global Psychotropic Drug Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Psychotropic Drug (Volume)
      • 5.3.1. Global Psychotropic Drug by: End-users (Volume)
        • 5.3.1.1. Hospitals
        • 5.3.1.2. Clinics
        • 5.3.1.3. Others
      • 5.3.2. Global Psychotropic Drug by: Distribution Channel (Volume)
        • 5.3.2.1. Hospital pharmacies
        • 5.3.2.2. Drug Stores
        • 5.3.2.3. Retail Stores
        • 5.3.2.4. E-Commerce
      • 5.3.3. Global Psychotropic Drug by: Drug Class (Volume)
        • 5.3.3.1. Anti-Depressants
        • 5.3.3.2. Anti-Psychotics
        • 5.3.3.3. Stimulants
        • 5.3.3.4. Anxiolytics
        • 5.3.3.5. Mood Stabilizers
      • 5.3.4. Global Psychotropic Drug Region
        • 5.3.4.1. South America
          • 5.3.4.1.1. Brazil
          • 5.3.4.1.2. Argentina
          • 5.3.4.1.3. Rest of South America
        • 5.3.4.2. Asia Pacific
          • 5.3.4.2.1. China
          • 5.3.4.2.2. Japan
          • 5.3.4.2.3. India
          • 5.3.4.2.4. South Korea
          • 5.3.4.2.5. Taiwan
          • 5.3.4.2.6. Australia
          • 5.3.4.2.7. Rest of Asia-Pacific
        • 5.3.4.3. Europe
          • 5.3.4.3.1. Germany
          • 5.3.4.3.2. France
          • 5.3.4.3.3. Italy
          • 5.3.4.3.4. United Kingdom
          • 5.3.4.3.5. Netherlands
          • 5.3.4.3.6. Rest of Europe
        • 5.3.4.4. MEA
          • 5.3.4.4.1. Middle East
          • 5.3.4.4.2. Africa
        • 5.3.4.5. North America
          • 5.3.4.5.1. United States
          • 5.3.4.5.2. Canada
          • 5.3.4.5.3. Mexico
    • 5.4. Global Psychotropic Drug (Price)
  • 6. Psychotropic Drug: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Intas Pharmaceuticals Ltd. (India)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Sun Pharmaceutical Industries Ltd. (India)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Cadila Pharmaceuticals (India)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Abbott Laboratories (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Sanofi S.A. (France)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Cipla Limited (India)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Biocon Limited (India)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Lupin Limited (India)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Emcure Pharmaceuticals Ltd. (India)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Novartis International AG (Switzerland)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Psychotropic Drug Sale, by End-users, Distribution Channel, Drug Class and Region (value, volume and price ) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Psychotropic Drug (Value)
      • 7.2.1. Global Psychotropic Drug by: End-users (Value)
        • 7.2.1.1. Hospitals
        • 7.2.1.2. Clinics
        • 7.2.1.3. Others
      • 7.2.2. Global Psychotropic Drug by: Distribution Channel (Value)
        • 7.2.2.1. Hospital pharmacies
        • 7.2.2.2. Drug Stores
        • 7.2.2.3. Retail Stores
        • 7.2.2.4. E-Commerce
      • 7.2.3. Global Psychotropic Drug by: Drug Class (Value)
        • 7.2.3.1. Anti-Depressants
        • 7.2.3.2. Anti-Psychotics
        • 7.2.3.3. Stimulants
        • 7.2.3.4. Anxiolytics
        • 7.2.3.5. Mood Stabilizers
      • 7.2.4. Global Psychotropic Drug Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Psychotropic Drug (Volume)
      • 7.3.1. Global Psychotropic Drug by: End-users (Volume)
        • 7.3.1.1. Hospitals
        • 7.3.1.2. Clinics
        • 7.3.1.3. Others
      • 7.3.2. Global Psychotropic Drug by: Distribution Channel (Volume)
        • 7.3.2.1. Hospital pharmacies
        • 7.3.2.2. Drug Stores
        • 7.3.2.3. Retail Stores
        • 7.3.2.4. E-Commerce
      • 7.3.3. Global Psychotropic Drug by: Drug Class (Volume)
        • 7.3.3.1. Anti-Depressants
        • 7.3.3.2. Anti-Psychotics
        • 7.3.3.3. Stimulants
        • 7.3.3.4. Anxiolytics
        • 7.3.3.5. Mood Stabilizers
      • 7.3.4. Global Psychotropic Drug Region
        • 7.3.4.1. South America
          • 7.3.4.1.1. Brazil
          • 7.3.4.1.2. Argentina
          • 7.3.4.1.3. Rest of South America
        • 7.3.4.2. Asia Pacific
          • 7.3.4.2.1. China
          • 7.3.4.2.2. Japan
          • 7.3.4.2.3. India
          • 7.3.4.2.4. South Korea
          • 7.3.4.2.5. Taiwan
          • 7.3.4.2.6. Australia
          • 7.3.4.2.7. Rest of Asia-Pacific
        • 7.3.4.3. Europe
          • 7.3.4.3.1. Germany
          • 7.3.4.3.2. France
          • 7.3.4.3.3. Italy
          • 7.3.4.3.4. United Kingdom
          • 7.3.4.3.5. Netherlands
          • 7.3.4.3.6. Rest of Europe
        • 7.3.4.4. MEA
          • 7.3.4.4.1. Middle East
          • 7.3.4.4.2. Africa
        • 7.3.4.5. North America
          • 7.3.4.5.1. United States
          • 7.3.4.5.2. Canada
          • 7.3.4.5.3. Mexico
    • 7.4. Global Psychotropic Drug (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Psychotropic Drug: by End-users(USD Million)
  • Table 2. Psychotropic Drug Hospitals , by Region USD Million (2017-2022)
  • Table 3. Psychotropic Drug Clinics , by Region USD Million (2017-2022)
  • Table 4. Psychotropic Drug Others , by Region USD Million (2017-2022)
  • Table 5. Psychotropic Drug: by Distribution Channel(USD Million)
  • Table 6. Psychotropic Drug Hospital pharmacies , by Region USD Million (2017-2022)
  • Table 7. Psychotropic Drug Drug Stores , by Region USD Million (2017-2022)
  • Table 8. Psychotropic Drug Retail Stores , by Region USD Million (2017-2022)
  • Table 9. Psychotropic Drug E-Commerce , by Region USD Million (2017-2022)
  • Table 10. Psychotropic Drug: by Drug Class(USD Million)
  • Table 11. Psychotropic Drug Anti-Depressants , by Region USD Million (2017-2022)
  • Table 12. Psychotropic Drug Anti-Psychotics , by Region USD Million (2017-2022)
  • Table 13. Psychotropic Drug Stimulants , by Region USD Million (2017-2022)
  • Table 14. Psychotropic Drug Anxiolytics , by Region USD Million (2017-2022)
  • Table 15. Psychotropic Drug Mood Stabilizers , by Region USD Million (2017-2022)
  • Table 16. South America Psychotropic Drug, by Country USD Million (2017-2022)
  • Table 17. South America Psychotropic Drug, by End-users USD Million (2017-2022)
  • Table 18. South America Psychotropic Drug, by Distribution Channel USD Million (2017-2022)
  • Table 19. South America Psychotropic Drug, by Drug Class USD Million (2017-2022)
  • Table 20. Brazil Psychotropic Drug, by End-users USD Million (2017-2022)
  • Table 21. Brazil Psychotropic Drug, by Distribution Channel USD Million (2017-2022)
  • Table 22. Brazil Psychotropic Drug, by Drug Class USD Million (2017-2022)
  • Table 23. Argentina Psychotropic Drug, by End-users USD Million (2017-2022)
  • Table 24. Argentina Psychotropic Drug, by Distribution Channel USD Million (2017-2022)
  • Table 25. Argentina Psychotropic Drug, by Drug Class USD Million (2017-2022)
  • Table 26. Rest of South America Psychotropic Drug, by End-users USD Million (2017-2022)
  • Table 27. Rest of South America Psychotropic Drug, by Distribution Channel USD Million (2017-2022)
  • Table 28. Rest of South America Psychotropic Drug, by Drug Class USD Million (2017-2022)
  • Table 29. Asia Pacific Psychotropic Drug, by Country USD Million (2017-2022)
  • Table 30. Asia Pacific Psychotropic Drug, by End-users USD Million (2017-2022)
  • Table 31. Asia Pacific Psychotropic Drug, by Distribution Channel USD Million (2017-2022)
  • Table 32. Asia Pacific Psychotropic Drug, by Drug Class USD Million (2017-2022)
  • Table 33. China Psychotropic Drug, by End-users USD Million (2017-2022)
  • Table 34. China Psychotropic Drug, by Distribution Channel USD Million (2017-2022)
  • Table 35. China Psychotropic Drug, by Drug Class USD Million (2017-2022)
  • Table 36. Japan Psychotropic Drug, by End-users USD Million (2017-2022)
  • Table 37. Japan Psychotropic Drug, by Distribution Channel USD Million (2017-2022)
  • Table 38. Japan Psychotropic Drug, by Drug Class USD Million (2017-2022)
  • Table 39. India Psychotropic Drug, by End-users USD Million (2017-2022)
  • Table 40. India Psychotropic Drug, by Distribution Channel USD Million (2017-2022)
  • Table 41. India Psychotropic Drug, by Drug Class USD Million (2017-2022)
  • Table 42. South Korea Psychotropic Drug, by End-users USD Million (2017-2022)
  • Table 43. South Korea Psychotropic Drug, by Distribution Channel USD Million (2017-2022)
  • Table 44. South Korea Psychotropic Drug, by Drug Class USD Million (2017-2022)
  • Table 45. Taiwan Psychotropic Drug, by End-users USD Million (2017-2022)
  • Table 46. Taiwan Psychotropic Drug, by Distribution Channel USD Million (2017-2022)
  • Table 47. Taiwan Psychotropic Drug, by Drug Class USD Million (2017-2022)
  • Table 48. Australia Psychotropic Drug, by End-users USD Million (2017-2022)
  • Table 49. Australia Psychotropic Drug, by Distribution Channel USD Million (2017-2022)
  • Table 50. Australia Psychotropic Drug, by Drug Class USD Million (2017-2022)
  • Table 51. Rest of Asia-Pacific Psychotropic Drug, by End-users USD Million (2017-2022)
  • Table 52. Rest of Asia-Pacific Psychotropic Drug, by Distribution Channel USD Million (2017-2022)
  • Table 53. Rest of Asia-Pacific Psychotropic Drug, by Drug Class USD Million (2017-2022)
  • Table 54. Europe Psychotropic Drug, by Country USD Million (2017-2022)
  • Table 55. Europe Psychotropic Drug, by End-users USD Million (2017-2022)
  • Table 56. Europe Psychotropic Drug, by Distribution Channel USD Million (2017-2022)
  • Table 57. Europe Psychotropic Drug, by Drug Class USD Million (2017-2022)
  • Table 58. Germany Psychotropic Drug, by End-users USD Million (2017-2022)
  • Table 59. Germany Psychotropic Drug, by Distribution Channel USD Million (2017-2022)
  • Table 60. Germany Psychotropic Drug, by Drug Class USD Million (2017-2022)
  • Table 61. France Psychotropic Drug, by End-users USD Million (2017-2022)
  • Table 62. France Psychotropic Drug, by Distribution Channel USD Million (2017-2022)
  • Table 63. France Psychotropic Drug, by Drug Class USD Million (2017-2022)
  • Table 64. Italy Psychotropic Drug, by End-users USD Million (2017-2022)
  • Table 65. Italy Psychotropic Drug, by Distribution Channel USD Million (2017-2022)
  • Table 66. Italy Psychotropic Drug, by Drug Class USD Million (2017-2022)
  • Table 67. United Kingdom Psychotropic Drug, by End-users USD Million (2017-2022)
  • Table 68. United Kingdom Psychotropic Drug, by Distribution Channel USD Million (2017-2022)
  • Table 69. United Kingdom Psychotropic Drug, by Drug Class USD Million (2017-2022)
  • Table 70. Netherlands Psychotropic Drug, by End-users USD Million (2017-2022)
  • Table 71. Netherlands Psychotropic Drug, by Distribution Channel USD Million (2017-2022)
  • Table 72. Netherlands Psychotropic Drug, by Drug Class USD Million (2017-2022)
  • Table 73. Rest of Europe Psychotropic Drug, by End-users USD Million (2017-2022)
  • Table 74. Rest of Europe Psychotropic Drug, by Distribution Channel USD Million (2017-2022)
  • Table 75. Rest of Europe Psychotropic Drug, by Drug Class USD Million (2017-2022)
  • Table 76. MEA Psychotropic Drug, by Country USD Million (2017-2022)
  • Table 77. MEA Psychotropic Drug, by End-users USD Million (2017-2022)
  • Table 78. MEA Psychotropic Drug, by Distribution Channel USD Million (2017-2022)
  • Table 79. MEA Psychotropic Drug, by Drug Class USD Million (2017-2022)
  • Table 80. Middle East Psychotropic Drug, by End-users USD Million (2017-2022)
  • Table 81. Middle East Psychotropic Drug, by Distribution Channel USD Million (2017-2022)
  • Table 82. Middle East Psychotropic Drug, by Drug Class USD Million (2017-2022)
  • Table 83. Africa Psychotropic Drug, by End-users USD Million (2017-2022)
  • Table 84. Africa Psychotropic Drug, by Distribution Channel USD Million (2017-2022)
  • Table 85. Africa Psychotropic Drug, by Drug Class USD Million (2017-2022)
  • Table 86. North America Psychotropic Drug, by Country USD Million (2017-2022)
  • Table 87. North America Psychotropic Drug, by End-users USD Million (2017-2022)
  • Table 88. North America Psychotropic Drug, by Distribution Channel USD Million (2017-2022)
  • Table 89. North America Psychotropic Drug, by Drug Class USD Million (2017-2022)
  • Table 90. United States Psychotropic Drug, by End-users USD Million (2017-2022)
  • Table 91. United States Psychotropic Drug, by Distribution Channel USD Million (2017-2022)
  • Table 92. United States Psychotropic Drug, by Drug Class USD Million (2017-2022)
  • Table 93. Canada Psychotropic Drug, by End-users USD Million (2017-2022)
  • Table 94. Canada Psychotropic Drug, by Distribution Channel USD Million (2017-2022)
  • Table 95. Canada Psychotropic Drug, by Drug Class USD Million (2017-2022)
  • Table 96. Mexico Psychotropic Drug, by End-users USD Million (2017-2022)
  • Table 97. Mexico Psychotropic Drug, by Distribution Channel USD Million (2017-2022)
  • Table 98. Mexico Psychotropic Drug, by Drug Class USD Million (2017-2022)
  • Table 99. Psychotropic Drug Sales: by End-users(K Units)
  • Table 100. Psychotropic Drug Sales Hospitals , by Region K Units (2017-2022)
  • Table 101. Psychotropic Drug Sales Clinics , by Region K Units (2017-2022)
  • Table 102. Psychotropic Drug Sales Others , by Region K Units (2017-2022)
  • Table 103. Psychotropic Drug Sales: by Distribution Channel(K Units)
  • Table 104. Psychotropic Drug Sales Hospital pharmacies , by Region K Units (2017-2022)
  • Table 105. Psychotropic Drug Sales Drug Stores , by Region K Units (2017-2022)
  • Table 106. Psychotropic Drug Sales Retail Stores , by Region K Units (2017-2022)
  • Table 107. Psychotropic Drug Sales E-Commerce , by Region K Units (2017-2022)
  • Table 108. Psychotropic Drug Sales: by Drug Class(K Units)
  • Table 109. Psychotropic Drug Sales Anti-Depressants , by Region K Units (2017-2022)
  • Table 110. Psychotropic Drug Sales Anti-Psychotics , by Region K Units (2017-2022)
  • Table 111. Psychotropic Drug Sales Stimulants , by Region K Units (2017-2022)
  • Table 112. Psychotropic Drug Sales Anxiolytics , by Region K Units (2017-2022)
  • Table 113. Psychotropic Drug Sales Mood Stabilizers , by Region K Units (2017-2022)
  • Table 114. South America Psychotropic Drug Sales, by Country K Units (2017-2022)
  • Table 115. South America Psychotropic Drug Sales, by End-users K Units (2017-2022)
  • Table 116. South America Psychotropic Drug Sales, by Distribution Channel K Units (2017-2022)
  • Table 117. South America Psychotropic Drug Sales, by Drug Class K Units (2017-2022)
  • Table 118. Brazil Psychotropic Drug Sales, by End-users K Units (2017-2022)
  • Table 119. Brazil Psychotropic Drug Sales, by Distribution Channel K Units (2017-2022)
  • Table 120. Brazil Psychotropic Drug Sales, by Drug Class K Units (2017-2022)
  • Table 121. Argentina Psychotropic Drug Sales, by End-users K Units (2017-2022)
  • Table 122. Argentina Psychotropic Drug Sales, by Distribution Channel K Units (2017-2022)
  • Table 123. Argentina Psychotropic Drug Sales, by Drug Class K Units (2017-2022)
  • Table 124. Rest of South America Psychotropic Drug Sales, by End-users K Units (2017-2022)
  • Table 125. Rest of South America Psychotropic Drug Sales, by Distribution Channel K Units (2017-2022)
  • Table 126. Rest of South America Psychotropic Drug Sales, by Drug Class K Units (2017-2022)
  • Table 127. Asia Pacific Psychotropic Drug Sales, by Country K Units (2017-2022)
  • Table 128. Asia Pacific Psychotropic Drug Sales, by End-users K Units (2017-2022)
  • Table 129. Asia Pacific Psychotropic Drug Sales, by Distribution Channel K Units (2017-2022)
  • Table 130. Asia Pacific Psychotropic Drug Sales, by Drug Class K Units (2017-2022)
  • Table 131. China Psychotropic Drug Sales, by End-users K Units (2017-2022)
  • Table 132. China Psychotropic Drug Sales, by Distribution Channel K Units (2017-2022)
  • Table 133. China Psychotropic Drug Sales, by Drug Class K Units (2017-2022)
  • Table 134. Japan Psychotropic Drug Sales, by End-users K Units (2017-2022)
  • Table 135. Japan Psychotropic Drug Sales, by Distribution Channel K Units (2017-2022)
  • Table 136. Japan Psychotropic Drug Sales, by Drug Class K Units (2017-2022)
  • Table 137. India Psychotropic Drug Sales, by End-users K Units (2017-2022)
  • Table 138. India Psychotropic Drug Sales, by Distribution Channel K Units (2017-2022)
  • Table 139. India Psychotropic Drug Sales, by Drug Class K Units (2017-2022)
  • Table 140. South Korea Psychotropic Drug Sales, by End-users K Units (2017-2022)
  • Table 141. South Korea Psychotropic Drug Sales, by Distribution Channel K Units (2017-2022)
  • Table 142. South Korea Psychotropic Drug Sales, by Drug Class K Units (2017-2022)
  • Table 143. Taiwan Psychotropic Drug Sales, by End-users K Units (2017-2022)
  • Table 144. Taiwan Psychotropic Drug Sales, by Distribution Channel K Units (2017-2022)
  • Table 145. Taiwan Psychotropic Drug Sales, by Drug Class K Units (2017-2022)
  • Table 146. Australia Psychotropic Drug Sales, by End-users K Units (2017-2022)
  • Table 147. Australia Psychotropic Drug Sales, by Distribution Channel K Units (2017-2022)
  • Table 148. Australia Psychotropic Drug Sales, by Drug Class K Units (2017-2022)
  • Table 149. Rest of Asia-Pacific Psychotropic Drug Sales, by End-users K Units (2017-2022)
  • Table 150. Rest of Asia-Pacific Psychotropic Drug Sales, by Distribution Channel K Units (2017-2022)
  • Table 151. Rest of Asia-Pacific Psychotropic Drug Sales, by Drug Class K Units (2017-2022)
  • Table 152. Europe Psychotropic Drug Sales, by Country K Units (2017-2022)
  • Table 153. Europe Psychotropic Drug Sales, by End-users K Units (2017-2022)
  • Table 154. Europe Psychotropic Drug Sales, by Distribution Channel K Units (2017-2022)
  • Table 155. Europe Psychotropic Drug Sales, by Drug Class K Units (2017-2022)
  • Table 156. Germany Psychotropic Drug Sales, by End-users K Units (2017-2022)
  • Table 157. Germany Psychotropic Drug Sales, by Distribution Channel K Units (2017-2022)
  • Table 158. Germany Psychotropic Drug Sales, by Drug Class K Units (2017-2022)
  • Table 159. France Psychotropic Drug Sales, by End-users K Units (2017-2022)
  • Table 160. France Psychotropic Drug Sales, by Distribution Channel K Units (2017-2022)
  • Table 161. France Psychotropic Drug Sales, by Drug Class K Units (2017-2022)
  • Table 162. Italy Psychotropic Drug Sales, by End-users K Units (2017-2022)
  • Table 163. Italy Psychotropic Drug Sales, by Distribution Channel K Units (2017-2022)
  • Table 164. Italy Psychotropic Drug Sales, by Drug Class K Units (2017-2022)
  • Table 165. United Kingdom Psychotropic Drug Sales, by End-users K Units (2017-2022)
  • Table 166. United Kingdom Psychotropic Drug Sales, by Distribution Channel K Units (2017-2022)
  • Table 167. United Kingdom Psychotropic Drug Sales, by Drug Class K Units (2017-2022)
  • Table 168. Netherlands Psychotropic Drug Sales, by End-users K Units (2017-2022)
  • Table 169. Netherlands Psychotropic Drug Sales, by Distribution Channel K Units (2017-2022)
  • Table 170. Netherlands Psychotropic Drug Sales, by Drug Class K Units (2017-2022)
  • Table 171. Rest of Europe Psychotropic Drug Sales, by End-users K Units (2017-2022)
  • Table 172. Rest of Europe Psychotropic Drug Sales, by Distribution Channel K Units (2017-2022)
  • Table 173. Rest of Europe Psychotropic Drug Sales, by Drug Class K Units (2017-2022)
  • Table 174. MEA Psychotropic Drug Sales, by Country K Units (2017-2022)
  • Table 175. MEA Psychotropic Drug Sales, by End-users K Units (2017-2022)
  • Table 176. MEA Psychotropic Drug Sales, by Distribution Channel K Units (2017-2022)
  • Table 177. MEA Psychotropic Drug Sales, by Drug Class K Units (2017-2022)
  • Table 178. Middle East Psychotropic Drug Sales, by End-users K Units (2017-2022)
  • Table 179. Middle East Psychotropic Drug Sales, by Distribution Channel K Units (2017-2022)
  • Table 180. Middle East Psychotropic Drug Sales, by Drug Class K Units (2017-2022)
  • Table 181. Africa Psychotropic Drug Sales, by End-users K Units (2017-2022)
  • Table 182. Africa Psychotropic Drug Sales, by Distribution Channel K Units (2017-2022)
  • Table 183. Africa Psychotropic Drug Sales, by Drug Class K Units (2017-2022)
  • Table 184. North America Psychotropic Drug Sales, by Country K Units (2017-2022)
  • Table 185. North America Psychotropic Drug Sales, by End-users K Units (2017-2022)
  • Table 186. North America Psychotropic Drug Sales, by Distribution Channel K Units (2017-2022)
  • Table 187. North America Psychotropic Drug Sales, by Drug Class K Units (2017-2022)
  • Table 188. United States Psychotropic Drug Sales, by End-users K Units (2017-2022)
  • Table 189. United States Psychotropic Drug Sales, by Distribution Channel K Units (2017-2022)
  • Table 190. United States Psychotropic Drug Sales, by Drug Class K Units (2017-2022)
  • Table 191. Canada Psychotropic Drug Sales, by End-users K Units (2017-2022)
  • Table 192. Canada Psychotropic Drug Sales, by Distribution Channel K Units (2017-2022)
  • Table 193. Canada Psychotropic Drug Sales, by Drug Class K Units (2017-2022)
  • Table 194. Mexico Psychotropic Drug Sales, by End-users K Units (2017-2022)
  • Table 195. Mexico Psychotropic Drug Sales, by Distribution Channel K Units (2017-2022)
  • Table 196. Mexico Psychotropic Drug Sales, by Drug Class K Units (2017-2022)
  • Table 197. Company Basic Information, Sales Area and Its Competitors
  • Table 198. Company Basic Information, Sales Area and Its Competitors
  • Table 199. Company Basic Information, Sales Area and Its Competitors
  • Table 200. Company Basic Information, Sales Area and Its Competitors
  • Table 201. Company Basic Information, Sales Area and Its Competitors
  • Table 202. Company Basic Information, Sales Area and Its Competitors
  • Table 203. Company Basic Information, Sales Area and Its Competitors
  • Table 204. Company Basic Information, Sales Area and Its Competitors
  • Table 205. Company Basic Information, Sales Area and Its Competitors
  • Table 206. Company Basic Information, Sales Area and Its Competitors
  • Table 207. Psychotropic Drug: by End-users(USD Million)
  • Table 208. Psychotropic Drug Hospitals , by Region USD Million (2023-2028)
  • Table 209. Psychotropic Drug Clinics , by Region USD Million (2023-2028)
  • Table 210. Psychotropic Drug Others , by Region USD Million (2023-2028)
  • Table 211. Psychotropic Drug: by Distribution Channel(USD Million)
  • Table 212. Psychotropic Drug Hospital pharmacies , by Region USD Million (2023-2028)
  • Table 213. Psychotropic Drug Drug Stores , by Region USD Million (2023-2028)
  • Table 214. Psychotropic Drug Retail Stores , by Region USD Million (2023-2028)
  • Table 215. Psychotropic Drug E-Commerce , by Region USD Million (2023-2028)
  • Table 216. Psychotropic Drug: by Drug Class(USD Million)
  • Table 217. Psychotropic Drug Anti-Depressants , by Region USD Million (2023-2028)
  • Table 218. Psychotropic Drug Anti-Psychotics , by Region USD Million (2023-2028)
  • Table 219. Psychotropic Drug Stimulants , by Region USD Million (2023-2028)
  • Table 220. Psychotropic Drug Anxiolytics , by Region USD Million (2023-2028)
  • Table 221. Psychotropic Drug Mood Stabilizers , by Region USD Million (2023-2028)
  • Table 222. South America Psychotropic Drug, by Country USD Million (2023-2028)
  • Table 223. South America Psychotropic Drug, by End-users USD Million (2023-2028)
  • Table 224. South America Psychotropic Drug, by Distribution Channel USD Million (2023-2028)
  • Table 225. South America Psychotropic Drug, by Drug Class USD Million (2023-2028)
  • Table 226. Brazil Psychotropic Drug, by End-users USD Million (2023-2028)
  • Table 227. Brazil Psychotropic Drug, by Distribution Channel USD Million (2023-2028)
  • Table 228. Brazil Psychotropic Drug, by Drug Class USD Million (2023-2028)
  • Table 229. Argentina Psychotropic Drug, by End-users USD Million (2023-2028)
  • Table 230. Argentina Psychotropic Drug, by Distribution Channel USD Million (2023-2028)
  • Table 231. Argentina Psychotropic Drug, by Drug Class USD Million (2023-2028)
  • Table 232. Rest of South America Psychotropic Drug, by End-users USD Million (2023-2028)
  • Table 233. Rest of South America Psychotropic Drug, by Distribution Channel USD Million (2023-2028)
  • Table 234. Rest of South America Psychotropic Drug, by Drug Class USD Million (2023-2028)
  • Table 235. Asia Pacific Psychotropic Drug, by Country USD Million (2023-2028)
  • Table 236. Asia Pacific Psychotropic Drug, by End-users USD Million (2023-2028)
  • Table 237. Asia Pacific Psychotropic Drug, by Distribution Channel USD Million (2023-2028)
  • Table 238. Asia Pacific Psychotropic Drug, by Drug Class USD Million (2023-2028)
  • Table 239. China Psychotropic Drug, by End-users USD Million (2023-2028)
  • Table 240. China Psychotropic Drug, by Distribution Channel USD Million (2023-2028)
  • Table 241. China Psychotropic Drug, by Drug Class USD Million (2023-2028)
  • Table 242. Japan Psychotropic Drug, by End-users USD Million (2023-2028)
  • Table 243. Japan Psychotropic Drug, by Distribution Channel USD Million (2023-2028)
  • Table 244. Japan Psychotropic Drug, by Drug Class USD Million (2023-2028)
  • Table 245. India Psychotropic Drug, by End-users USD Million (2023-2028)
  • Table 246. India Psychotropic Drug, by Distribution Channel USD Million (2023-2028)
  • Table 247. India Psychotropic Drug, by Drug Class USD Million (2023-2028)
  • Table 248. South Korea Psychotropic Drug, by End-users USD Million (2023-2028)
  • Table 249. South Korea Psychotropic Drug, by Distribution Channel USD Million (2023-2028)
  • Table 250. South Korea Psychotropic Drug, by Drug Class USD Million (2023-2028)
  • Table 251. Taiwan Psychotropic Drug, by End-users USD Million (2023-2028)
  • Table 252. Taiwan Psychotropic Drug, by Distribution Channel USD Million (2023-2028)
  • Table 253. Taiwan Psychotropic Drug, by Drug Class USD Million (2023-2028)
  • Table 254. Australia Psychotropic Drug, by End-users USD Million (2023-2028)
  • Table 255. Australia Psychotropic Drug, by Distribution Channel USD Million (2023-2028)
  • Table 256. Australia Psychotropic Drug, by Drug Class USD Million (2023-2028)
  • Table 257. Rest of Asia-Pacific Psychotropic Drug, by End-users USD Million (2023-2028)
  • Table 258. Rest of Asia-Pacific Psychotropic Drug, by Distribution Channel USD Million (2023-2028)
  • Table 259. Rest of Asia-Pacific Psychotropic Drug, by Drug Class USD Million (2023-2028)
  • Table 260. Europe Psychotropic Drug, by Country USD Million (2023-2028)
  • Table 261. Europe Psychotropic Drug, by End-users USD Million (2023-2028)
  • Table 262. Europe Psychotropic Drug, by Distribution Channel USD Million (2023-2028)
  • Table 263. Europe Psychotropic Drug, by Drug Class USD Million (2023-2028)
  • Table 264. Germany Psychotropic Drug, by End-users USD Million (2023-2028)
  • Table 265. Germany Psychotropic Drug, by Distribution Channel USD Million (2023-2028)
  • Table 266. Germany Psychotropic Drug, by Drug Class USD Million (2023-2028)
  • Table 267. France Psychotropic Drug, by End-users USD Million (2023-2028)
  • Table 268. France Psychotropic Drug, by Distribution Channel USD Million (2023-2028)
  • Table 269. France Psychotropic Drug, by Drug Class USD Million (2023-2028)
  • Table 270. Italy Psychotropic Drug, by End-users USD Million (2023-2028)
  • Table 271. Italy Psychotropic Drug, by Distribution Channel USD Million (2023-2028)
  • Table 272. Italy Psychotropic Drug, by Drug Class USD Million (2023-2028)
  • Table 273. United Kingdom Psychotropic Drug, by End-users USD Million (2023-2028)
  • Table 274. United Kingdom Psychotropic Drug, by Distribution Channel USD Million (2023-2028)
  • Table 275. United Kingdom Psychotropic Drug, by Drug Class USD Million (2023-2028)
  • Table 276. Netherlands Psychotropic Drug, by End-users USD Million (2023-2028)
  • Table 277. Netherlands Psychotropic Drug, by Distribution Channel USD Million (2023-2028)
  • Table 278. Netherlands Psychotropic Drug, by Drug Class USD Million (2023-2028)
  • Table 279. Rest of Europe Psychotropic Drug, by End-users USD Million (2023-2028)
  • Table 280. Rest of Europe Psychotropic Drug, by Distribution Channel USD Million (2023-2028)
  • Table 281. Rest of Europe Psychotropic Drug, by Drug Class USD Million (2023-2028)
  • Table 282. MEA Psychotropic Drug, by Country USD Million (2023-2028)
  • Table 283. MEA Psychotropic Drug, by End-users USD Million (2023-2028)
  • Table 284. MEA Psychotropic Drug, by Distribution Channel USD Million (2023-2028)
  • Table 285. MEA Psychotropic Drug, by Drug Class USD Million (2023-2028)
  • Table 286. Middle East Psychotropic Drug, by End-users USD Million (2023-2028)
  • Table 287. Middle East Psychotropic Drug, by Distribution Channel USD Million (2023-2028)
  • Table 288. Middle East Psychotropic Drug, by Drug Class USD Million (2023-2028)
  • Table 289. Africa Psychotropic Drug, by End-users USD Million (2023-2028)
  • Table 290. Africa Psychotropic Drug, by Distribution Channel USD Million (2023-2028)
  • Table 291. Africa Psychotropic Drug, by Drug Class USD Million (2023-2028)
  • Table 292. North America Psychotropic Drug, by Country USD Million (2023-2028)
  • Table 293. North America Psychotropic Drug, by End-users USD Million (2023-2028)
  • Table 294. North America Psychotropic Drug, by Distribution Channel USD Million (2023-2028)
  • Table 295. North America Psychotropic Drug, by Drug Class USD Million (2023-2028)
  • Table 296. United States Psychotropic Drug, by End-users USD Million (2023-2028)
  • Table 297. United States Psychotropic Drug, by Distribution Channel USD Million (2023-2028)
  • Table 298. United States Psychotropic Drug, by Drug Class USD Million (2023-2028)
  • Table 299. Canada Psychotropic Drug, by End-users USD Million (2023-2028)
  • Table 300. Canada Psychotropic Drug, by Distribution Channel USD Million (2023-2028)
  • Table 301. Canada Psychotropic Drug, by Drug Class USD Million (2023-2028)
  • Table 302. Mexico Psychotropic Drug, by End-users USD Million (2023-2028)
  • Table 303. Mexico Psychotropic Drug, by Distribution Channel USD Million (2023-2028)
  • Table 304. Mexico Psychotropic Drug, by Drug Class USD Million (2023-2028)
  • Table 305. Psychotropic Drug Sales: by End-users(K Units)
  • Table 306. Psychotropic Drug Sales Hospitals , by Region K Units (2023-2028)
  • Table 307. Psychotropic Drug Sales Clinics , by Region K Units (2023-2028)
  • Table 308. Psychotropic Drug Sales Others , by Region K Units (2023-2028)
  • Table 309. Psychotropic Drug Sales: by Distribution Channel(K Units)
  • Table 310. Psychotropic Drug Sales Hospital pharmacies , by Region K Units (2023-2028)
  • Table 311. Psychotropic Drug Sales Drug Stores , by Region K Units (2023-2028)
  • Table 312. Psychotropic Drug Sales Retail Stores , by Region K Units (2023-2028)
  • Table 313. Psychotropic Drug Sales E-Commerce , by Region K Units (2023-2028)
  • Table 314. Psychotropic Drug Sales: by Drug Class(K Units)
  • Table 315. Psychotropic Drug Sales Anti-Depressants , by Region K Units (2023-2028)
  • Table 316. Psychotropic Drug Sales Anti-Psychotics , by Region K Units (2023-2028)
  • Table 317. Psychotropic Drug Sales Stimulants , by Region K Units (2023-2028)
  • Table 318. Psychotropic Drug Sales Anxiolytics , by Region K Units (2023-2028)
  • Table 319. Psychotropic Drug Sales Mood Stabilizers , by Region K Units (2023-2028)
  • Table 320. South America Psychotropic Drug Sales, by Country K Units (2023-2028)
  • Table 321. South America Psychotropic Drug Sales, by End-users K Units (2023-2028)
  • Table 322. South America Psychotropic Drug Sales, by Distribution Channel K Units (2023-2028)
  • Table 323. South America Psychotropic Drug Sales, by Drug Class K Units (2023-2028)
  • Table 324. Brazil Psychotropic Drug Sales, by End-users K Units (2023-2028)
  • Table 325. Brazil Psychotropic Drug Sales, by Distribution Channel K Units (2023-2028)
  • Table 326. Brazil Psychotropic Drug Sales, by Drug Class K Units (2023-2028)
  • Table 327. Argentina Psychotropic Drug Sales, by End-users K Units (2023-2028)
  • Table 328. Argentina Psychotropic Drug Sales, by Distribution Channel K Units (2023-2028)
  • Table 329. Argentina Psychotropic Drug Sales, by Drug Class K Units (2023-2028)
  • Table 330. Rest of South America Psychotropic Drug Sales, by End-users K Units (2023-2028)
  • Table 331. Rest of South America Psychotropic Drug Sales, by Distribution Channel K Units (2023-2028)
  • Table 332. Rest of South America Psychotropic Drug Sales, by Drug Class K Units (2023-2028)
  • Table 333. Asia Pacific Psychotropic Drug Sales, by Country K Units (2023-2028)
  • Table 334. Asia Pacific Psychotropic Drug Sales, by End-users K Units (2023-2028)
  • Table 335. Asia Pacific Psychotropic Drug Sales, by Distribution Channel K Units (2023-2028)
  • Table 336. Asia Pacific Psychotropic Drug Sales, by Drug Class K Units (2023-2028)
  • Table 337. China Psychotropic Drug Sales, by End-users K Units (2023-2028)
  • Table 338. China Psychotropic Drug Sales, by Distribution Channel K Units (2023-2028)
  • Table 339. China Psychotropic Drug Sales, by Drug Class K Units (2023-2028)
  • Table 340. Japan Psychotropic Drug Sales, by End-users K Units (2023-2028)
  • Table 341. Japan Psychotropic Drug Sales, by Distribution Channel K Units (2023-2028)
  • Table 342. Japan Psychotropic Drug Sales, by Drug Class K Units (2023-2028)
  • Table 343. India Psychotropic Drug Sales, by End-users K Units (2023-2028)
  • Table 344. India Psychotropic Drug Sales, by Distribution Channel K Units (2023-2028)
  • Table 345. India Psychotropic Drug Sales, by Drug Class K Units (2023-2028)
  • Table 346. South Korea Psychotropic Drug Sales, by End-users K Units (2023-2028)
  • Table 347. South Korea Psychotropic Drug Sales, by Distribution Channel K Units (2023-2028)
  • Table 348. South Korea Psychotropic Drug Sales, by Drug Class K Units (2023-2028)
  • Table 349. Taiwan Psychotropic Drug Sales, by End-users K Units (2023-2028)
  • Table 350. Taiwan Psychotropic Drug Sales, by Distribution Channel K Units (2023-2028)
  • Table 351. Taiwan Psychotropic Drug Sales, by Drug Class K Units (2023-2028)
  • Table 352. Australia Psychotropic Drug Sales, by End-users K Units (2023-2028)
  • Table 353. Australia Psychotropic Drug Sales, by Distribution Channel K Units (2023-2028)
  • Table 354. Australia Psychotropic Drug Sales, by Drug Class K Units (2023-2028)
  • Table 355. Rest of Asia-Pacific Psychotropic Drug Sales, by End-users K Units (2023-2028)
  • Table 356. Rest of Asia-Pacific Psychotropic Drug Sales, by Distribution Channel K Units (2023-2028)
  • Table 357. Rest of Asia-Pacific Psychotropic Drug Sales, by Drug Class K Units (2023-2028)
  • Table 358. Europe Psychotropic Drug Sales, by Country K Units (2023-2028)
  • Table 359. Europe Psychotropic Drug Sales, by End-users K Units (2023-2028)
  • Table 360. Europe Psychotropic Drug Sales, by Distribution Channel K Units (2023-2028)
  • Table 361. Europe Psychotropic Drug Sales, by Drug Class K Units (2023-2028)
  • Table 362. Germany Psychotropic Drug Sales, by End-users K Units (2023-2028)
  • Table 363. Germany Psychotropic Drug Sales, by Distribution Channel K Units (2023-2028)
  • Table 364. Germany Psychotropic Drug Sales, by Drug Class K Units (2023-2028)
  • Table 365. France Psychotropic Drug Sales, by End-users K Units (2023-2028)
  • Table 366. France Psychotropic Drug Sales, by Distribution Channel K Units (2023-2028)
  • Table 367. France Psychotropic Drug Sales, by Drug Class K Units (2023-2028)
  • Table 368. Italy Psychotropic Drug Sales, by End-users K Units (2023-2028)
  • Table 369. Italy Psychotropic Drug Sales, by Distribution Channel K Units (2023-2028)
  • Table 370. Italy Psychotropic Drug Sales, by Drug Class K Units (2023-2028)
  • Table 371. United Kingdom Psychotropic Drug Sales, by End-users K Units (2023-2028)
  • Table 372. United Kingdom Psychotropic Drug Sales, by Distribution Channel K Units (2023-2028)
  • Table 373. United Kingdom Psychotropic Drug Sales, by Drug Class K Units (2023-2028)
  • Table 374. Netherlands Psychotropic Drug Sales, by End-users K Units (2023-2028)
  • Table 375. Netherlands Psychotropic Drug Sales, by Distribution Channel K Units (2023-2028)
  • Table 376. Netherlands Psychotropic Drug Sales, by Drug Class K Units (2023-2028)
  • Table 377. Rest of Europe Psychotropic Drug Sales, by End-users K Units (2023-2028)
  • Table 378. Rest of Europe Psychotropic Drug Sales, by Distribution Channel K Units (2023-2028)
  • Table 379. Rest of Europe Psychotropic Drug Sales, by Drug Class K Units (2023-2028)
  • Table 380. MEA Psychotropic Drug Sales, by Country K Units (2023-2028)
  • Table 381. MEA Psychotropic Drug Sales, by End-users K Units (2023-2028)
  • Table 382. MEA Psychotropic Drug Sales, by Distribution Channel K Units (2023-2028)
  • Table 383. MEA Psychotropic Drug Sales, by Drug Class K Units (2023-2028)
  • Table 384. Middle East Psychotropic Drug Sales, by End-users K Units (2023-2028)
  • Table 385. Middle East Psychotropic Drug Sales, by Distribution Channel K Units (2023-2028)
  • Table 386. Middle East Psychotropic Drug Sales, by Drug Class K Units (2023-2028)
  • Table 387. Africa Psychotropic Drug Sales, by End-users K Units (2023-2028)
  • Table 388. Africa Psychotropic Drug Sales, by Distribution Channel K Units (2023-2028)
  • Table 389. Africa Psychotropic Drug Sales, by Drug Class K Units (2023-2028)
  • Table 390. North America Psychotropic Drug Sales, by Country K Units (2023-2028)
  • Table 391. North America Psychotropic Drug Sales, by End-users K Units (2023-2028)
  • Table 392. North America Psychotropic Drug Sales, by Distribution Channel K Units (2023-2028)
  • Table 393. North America Psychotropic Drug Sales, by Drug Class K Units (2023-2028)
  • Table 394. United States Psychotropic Drug Sales, by End-users K Units (2023-2028)
  • Table 395. United States Psychotropic Drug Sales, by Distribution Channel K Units (2023-2028)
  • Table 396. United States Psychotropic Drug Sales, by Drug Class K Units (2023-2028)
  • Table 397. Canada Psychotropic Drug Sales, by End-users K Units (2023-2028)
  • Table 398. Canada Psychotropic Drug Sales, by Distribution Channel K Units (2023-2028)
  • Table 399. Canada Psychotropic Drug Sales, by Drug Class K Units (2023-2028)
  • Table 400. Mexico Psychotropic Drug Sales, by End-users K Units (2023-2028)
  • Table 401. Mexico Psychotropic Drug Sales, by Distribution Channel K Units (2023-2028)
  • Table 402. Mexico Psychotropic Drug Sales, by Drug Class K Units (2023-2028)
  • Table 403. Research Programs/Design for This Report
  • Table 404. Key Data Information from Secondary Sources
  • Table 405. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Psychotropic Drug: by End-users USD Million (2017-2022)
  • Figure 5. Global Psychotropic Drug: by Distribution Channel USD Million (2017-2022)
  • Figure 6. Global Psychotropic Drug: by Drug Class USD Million (2017-2022)
  • Figure 7. South America Psychotropic Drug Share (%), by Country
  • Figure 8. Asia Pacific Psychotropic Drug Share (%), by Country
  • Figure 9. Europe Psychotropic Drug Share (%), by Country
  • Figure 10. MEA Psychotropic Drug Share (%), by Country
  • Figure 11. North America Psychotropic Drug Share (%), by Country
  • Figure 12. Global Psychotropic Drug: by End-users K Units (2017-2022)
  • Figure 13. Global Psychotropic Drug: by Distribution Channel K Units (2017-2022)
  • Figure 14. Global Psychotropic Drug: by Drug Class K Units (2017-2022)
  • Figure 15. South America Psychotropic Drug Share (%), by Country
  • Figure 16. Asia Pacific Psychotropic Drug Share (%), by Country
  • Figure 17. Europe Psychotropic Drug Share (%), by Country
  • Figure 18. MEA Psychotropic Drug Share (%), by Country
  • Figure 19. North America Psychotropic Drug Share (%), by Country
  • Figure 20. Global Psychotropic Drug share by Players 2022 (%)
  • Figure 21. Global Psychotropic Drug share by Players (Top 3) 2022(%)
  • Figure 22. Global Psychotropic Drug share by Players (Top 5) 2022(%)
  • Figure 23. BCG Matrix for key Companies
  • Figure 24. Intas Pharmaceuticals Ltd. (India) Revenue, Net Income and Gross profit
  • Figure 25. Intas Pharmaceuticals Ltd. (India) Revenue: by Geography 2022
  • Figure 26. Sun Pharmaceutical Industries Ltd. (India) Revenue, Net Income and Gross profit
  • Figure 27. Sun Pharmaceutical Industries Ltd. (India) Revenue: by Geography 2022
  • Figure 28. Cadila Pharmaceuticals (India) Revenue, Net Income and Gross profit
  • Figure 29. Cadila Pharmaceuticals (India) Revenue: by Geography 2022
  • Figure 30. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 31. Abbott Laboratories (United States) Revenue: by Geography 2022
  • Figure 32. Sanofi S.A. (France) Revenue, Net Income and Gross profit
  • Figure 33. Sanofi S.A. (France) Revenue: by Geography 2022
  • Figure 34. Cipla Limited (India) Revenue, Net Income and Gross profit
  • Figure 35. Cipla Limited (India) Revenue: by Geography 2022
  • Figure 36. Biocon Limited (India) Revenue, Net Income and Gross profit
  • Figure 37. Biocon Limited (India) Revenue: by Geography 2022
  • Figure 38. Lupin Limited (India) Revenue, Net Income and Gross profit
  • Figure 39. Lupin Limited (India) Revenue: by Geography 2022
  • Figure 40. Emcure Pharmaceuticals Ltd. (India) Revenue, Net Income and Gross profit
  • Figure 41. Emcure Pharmaceuticals Ltd. (India) Revenue: by Geography 2022
  • Figure 42. Novartis International AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 43. Novartis International AG (Switzerland) Revenue: by Geography 2022
  • Figure 44. Global Psychotropic Drug: by End-users USD Million (2023-2028)
  • Figure 45. Global Psychotropic Drug: by Distribution Channel USD Million (2023-2028)
  • Figure 46. Global Psychotropic Drug: by Drug Class USD Million (2023-2028)
  • Figure 47. South America Psychotropic Drug Share (%), by Country
  • Figure 48. Asia Pacific Psychotropic Drug Share (%), by Country
  • Figure 49. Europe Psychotropic Drug Share (%), by Country
  • Figure 50. MEA Psychotropic Drug Share (%), by Country
  • Figure 51. North America Psychotropic Drug Share (%), by Country
  • Figure 52. Global Psychotropic Drug: by End-users K Units (2023-2028)
  • Figure 53. Global Psychotropic Drug: by Distribution Channel K Units (2023-2028)
  • Figure 54. Global Psychotropic Drug: by Drug Class K Units (2023-2028)
  • Figure 55. South America Psychotropic Drug Share (%), by Country
  • Figure 56. Asia Pacific Psychotropic Drug Share (%), by Country
  • Figure 57. Europe Psychotropic Drug Share (%), by Country
  • Figure 58. MEA Psychotropic Drug Share (%), by Country
  • Figure 59. North America Psychotropic Drug Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Intas Pharmaceuticals Ltd. (India)
  • Sun Pharmaceutical Industries Ltd. (India)
  • Cadila Pharmaceuticals (India)
  • Abbott Laboratories (United States)
  • Sanofi S.A. (France)
  • Cipla Limited (India)
  • Biocon Limited (India)
  • Lupin Limited (India)
  • Emcure Pharmaceuticals Ltd. (India)
  • Novartis International AG (Switzerland)
Additional players considered in the study are as follows:
Dr. Reddy’s Laboratories Limited (India) , Alkem Laboratories Limited (India)
Select User Access Type

Key Highlights of Report


Jun 2023 214 Pages 55 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Psychotropic Drug Market Quantitative research analysis
Global Psychotropic Drug Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

"Increased Prevalence of Psychotic Disorders " is seen as one of major growth factors of Psychotropic Drug Market in years to come.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
The Psychotropic Drug market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete of companies available in our research coverage.

Know More About Global Psychotropic Drug Market Report?

Have a Query? Click Here

Other Related Reports

Amoxicillin Sodium Comprehensive Study by Type (Capsules, Tablets, Chewable Tablets, Powder), Application (Humans, Animals), Route of Administration (Injectable, Oral), Distribution Channel (Offline ...
$ 3350
Motion Sickness Treatment Comprehensive Study by Type (Anticholinergic, Antihistamines), Route of Administration (Oral, Transdermal, Parenteral, Other), Distribution Channel (Retail Pharmacies, Onlin...
$ 3350
Sickle Cell Anemia Drug Comprehensive Study by Type (Antibiotics, Hydroxyurea, Pain-relieving medications, Others), Mode of Administration (Oral, Intravenous), Disease Type (Sickle cell anemia, Sickl...
$ 3650
Multiple Sclerosis Comprehensive Study by Type (Clinically Isolated Syndrome, Relapsing-remitting, Secondary progressive, Primary progressive, Progressive-relapsing), Distribution Channel (Hospitals ...
$ 3800
Folinic Acid Comprehensive Study by Application (Hospitals, Pharmaceuticals, Nutraceutical, Food and Beverages, Others), Form (Tablets, Injection, Others), Distribution Channels (Online, Offline) Pla...
$ 3500
Ipecac Comprehensive Study by Type (Powder, Liquid (Syrup)), Application (Hospitals, Clinics), Distribution Channel (Online, Offline) Players and Region - Global Market Outlook to 2024
$ 3500